tanios bekaii-saab, md, comments on dosing regorafenib (stivarga) in 3rd line treatment of mcrc
Published 8 years ago • 74 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
2:19
tanios bekali-saab, md, on utilizing regorafenib (stivarga) and trifluridine (lonserf)
-
1:39
dr. bekaii-saab on dosing strategies with regorafenib in crc
-
1:12
tanios bekaii-saab, md: mechanisms of action in regorafenib
-
0:50
tanios bekaii-saab, md, on performance status when selecting mcrc, 3rd line treatment therapy
-
0:28
tanios bekaii-saab, md: reinitiating regorafenib in patients with mcrc
-
5:19
stivarga moa. austin visuals
-
1:28:39
immune 36: aberrant immunity in covid-19
-
58:04
kravis wise lecture: viviane tabar, md
-
1:16
dr. bekaii-saab on tas-102 and regorafenib in mcrc
-
1:20
tanios bekaii-saab, md: clinical data supporting regorafenib in mcrc
-
1:21
tanios bekaii-saab, md: regorafenib dose adjustments
-
1:20
dr. bekaii-saab on the use of regorafenib in patients with mcrc
-
0:56
philip philip, md on stivarga (regorafenib) dosage in 2nd line treatment of mcrc
-
0:57
dr. bekaii-saab discusses the next steps with regorafenib in crc
-
1:45
jeffrey a. meyerhardt, md explains integration of stivarga and lonserf in later lines of treatment
-
1:21
dr. bekaii-saab discusses regorafenib use in mcrc
-
2:26
dr. bekaii-saab on the impact of regorafenib in crc
-
8:47
colorectal cancer: dosing strategies with regorafenib
-
2:22
dr. tanios bekaii-saab on new agents to treat colorectal cancer
-
1:30
tanios bekaii-saab, md on msi-high as an mcrc response predictor to nivolumab (opdivo)
-
2:27
dr. bekaii-saab on the redos study in metastatic colorectal cancer
-
6:43
tanios bekaii-saab md, facp, discusses changes in treatment for crc patients resulting from covid-19